Transcatheter arterial infusion therapy in the treatment of advanced pancreatic cancer: a feasibility study

Cardiovasc Intervent Radiol. 1999 May-Jun;22(3):196-200. doi: 10.1007/s002709900365.

Abstract

Purpose: To evaluate the effects of transcatheter arterial infusion (TAI) therapy in 18 patients with advanced pancreatic cancer.

Methods: The drugs infused were epirubicin 60 mg, mitomycin C 20 mg, and 5-fluorouracil 500 mg. The efficacy of TAI was evaluated by a tumor marker (CA19-9), computed tomography (CT) findings, and postoperative histopathological specimens.

Results: In 10 of 15 cases, the tumor marker level was decreased after TAI therapy. In 6 of 14 cases, CT showed a decrease in the tumor size, and in 1 case, the tumor disappeared completely. In 6 cases the tumor could be resected. Necrosis, fibrosis, and degeneration of cancer cells were seen in 3 of 4 cases for whom a histopathological evaluation was done. The median survival was 11 months. In 17 patients back pain was the chief complaint, and was reduced to a self-controlled level in 10 patients following TAI therapy. No major complications were encountered.

Conclusion: TAI appears to be an effective palliative treatment for advanced pancreatic cancer.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • CA-19-9 Antigen / blood
  • Epirubicin / administration & dosage
  • Feasibility Studies
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Infusions, Intra-Arterial*
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage
  • Palliative Care / methods*
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / mortality
  • Survival Analysis
  • Tomography, X-Ray Computed

Substances

  • CA-19-9 Antigen
  • Epirubicin
  • Mitomycin
  • Fluorouracil